Key Highlights
- Emergent BioSolutions surged on unconfirmed reports of a suspected plague case at a Russian research institute.
- The case has not been confirmed as plague, with officials describing it as a pneumonia of unknown origin.
- Emergent develops vaccines and treatments for threats such as anthrax and smallpox, with governments among its customers.
- Novavax also surged on the same reports even though its vaccines target viral, not bacterial, diseases.
Emergent BioSolutions shares surged on Monday as traders bid up biodefense names after reports of a suspected plague case at a Russian research institute, a case that has not been confirmed.
The Trigger
Emergent BioSolutions (NYSE:EBS) surged on Monday, Oct. 5, landing among the top gainers on the Russell 2000. The stock was reported near $7.57, though reports differed on the size of the gain.
The move came after reports of a suspected plague death of a worker at Russia's Irkutsk Anti-Plague Research Institute. Plague has not been confirmed; the case has been described in reports as a pneumonia of unknown origin, meaning its cause had not been identified.
According to reports, at least 197 people were under observation or quarantine, and US Secretary of State Marco Rubio was monitoring the situation. The State Department said it was acting in coordination with the Centers for Disease Control and Prevention and interagency partners, pressing Moscow to share accurate and timely information.
Irkutsk Governor Igor Kobzev offered an update, saying that over the past few days, no new cases of staff from the Anti-Plague Institute seeking medical attention had been identified.
That statement, along with the lack of confirmation, is an important part of the picture. Markets sometimes react quickly to early health headlines before facts are established, and moves on unconfirmed reports can be volatile. Biodefense stocks in particular tend to respond to any sign of a new biological threat, regardless of how serious it ultimately proves.
What Emergent Does
Emergent BioSolutions focuses on public-health preparedness. It develops and supplies vaccines and treatments for threats such as anthrax and smallpox, as well as opioid-overdose treatment, and counts governments among its major customers.
That profile makes it a go-to name for traders when biological threats are in the news. Headlines about infectious disease, even unconfirmed ones, can lift the stock as investors consider potential government Demand for preparedness products.
Vaccines and Biodefense Rally Together
Emergent was not alone. Novavax (NASDAQ:NVAX) also surged on the same Russian reports, even though plague is a bacterial disease while Novavax makes protein-based viral vaccines. Vaccine names had another lift from Vaxcyte (NASDAQ:PCVX), which soared after positive late-stage data for its pneumococcal vaccine candidate.
Elsewhere in health care, the picture was weaker. The sector was the worst performer at midday, with Merck (NYSE:MRK) the worst stock in the Dow and Bristol-Myers Squibb (NYSE:BMY) lower after a Leerink Partners downgrade.
The Market Backdrop
The broader market was positive. The Russell 2000 gained 14.24 points to 2,847.14. The Nasdaq Composite climbed 286.45 points to a record 27,477.31, the S&P 500 rose 51.23 points to 7,773.95, just shy of its summer record, and the Dow added 90.94 points to 51,267.90.
Friday's weak September jobs report, which showed payrolls rising by just 29,000, cut bets on another Fed rate hike in October. But the 10-year Treasury Yield still climbed to its highest level since 2002, and the ISM services survey showed prices paid at their highest since July 2022.
What to Watch Next
The biggest variable is whether health officials confirm or rule out plague in the Russian case, and whether any new cases emerge. So far, the Irkutsk governor has said no new cases among institute staff were identified.
For Emergent, headline-driven moves can fade as quickly as they arrive, so its next Quarterly Report will offer a firmer read on government orders. The Fed releases minutes from its September meeting on Wednesday, Oct. 7, at 2 p.m. ET.






Please wait processing your request...